AstraZeneca has signed an AI-led research agreement with China's CSPC Pharmaceutical Group worth up to $5.3 billion, which would help the Anglo-Swedish drugmaker develop therapies for chronic ...

AstraZeneca (LSE:AZN) recently announced that its investigational antibody, anselamimab, did not achieve statistical ...

AstraZeneca Plc (NASDAQ:AZN) released high-level results from the Cardiac Amyloid Reaching for Extended Survival (CARES) ...

AstraZeneca said it entered into a strategic research collaboration with China’s CSPC Pharmaceuticals, focused on artificial intelligence-driven research, valued at up to $5.33 billion.

AstraZeneca has joined the long list of big pharma companies enlisting the services of Chinese biotechs, signing a deal worth up to $5.2bn with CSPC Pharmaceuticals to research chronic disease drug ...

AstraZeneca inks a multibillion-dollar deal with CSPC to co-develop AI-driven therapies for chronic and immune diseases, boosting its presence in China.

This collaboration represents a significant financial commitment from AstraZeneca, with the total potential value of the deal reaching $5.33 billion if all milestones are achieved.

AstraZeneca chief executive Sir Pascal Soriot is reportedly considering the move due to growing frustration with the UK's rules on approving new medicines as well as a row over drug prices.

AstraZeneca has entered a strategic research collaboration with China's CSPC Pharmaceutical Group, aiming to accelerate the discovery of novel oral therapies for chronic diseases. The partnership, ...

Under the terms of the agreement, CSPC will receive $110 million as an upfront payment. The deal also includes potential milestone payments of up to $5.22 billion. The partnership aims to strengthen ...